Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK4 | Q13043 | 1/20 | 0.43 |
| ▸ | STK3 | Q13188 | 1/20 | 0.43 |
| ▸ | VCP | P55072 | 4/20 | 0.41 |
| ▸ | MAT2A | P31153 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 4/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582009 | 0.88 | ADORA1 (0.41) | MAT2AADORA1 | |
| SCHEMBL5582140 | 0.86 | ADORA1 (0.50) | PIM1PIM2ADORA1 | |
| SCHEMBL5582126 | 0.85 | PDE5A (0.43) | ADORA1 | |
| SCHEMBL5582085 | 0.84 | CSNK2A2 (0.38) | ADORA1 | |
| SCHEMBL5582252 | 0.83 | VCP (0.44) | STK4STK3VCPADORA1 | |
| SCHEMBL5581817 | 0.82 | CSNK2A2 (0.41) | ADORA1 | |
| SCHEMBL5581989 | 0.78 | DHFR (0.51) | ADORA1 | |
| SCHEMBL5581717 | 0.78 | TSHR (0.39) | ADORA1 | |
| SCHEMBL5582020 | 0.77 | ADORA1 (0.40) | ADORA1 | |
| SCHEMBL5582200 | 0.76 | MAPT (0.43) | STK4STK3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | KYOWA HAKKO KOGYO CO.,LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1726584-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | AGTR2, ABL1, AGTR1 | STK4 1193/4885STK3 1353/4885VCP 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.